Atropos Health, a leading innovator in real-world data platforms, has officially launched its cutting-edge AI solution, ChatRWD, after a successful beta program. This generative AI tool is designed to help clinicians and researchers generate high-quality, publication-grade real-world evidence in minutes—reducing the process from months to mere moments.
Revolutionizing Observational Studies with ChatRWD A year after introducing its operating system, Geneva OS, and a chatbot interface to streamline the generation of observational studies, Atropos Health is now offering ChatRWD more broadly. By leveraging generative AI, ChatRWD enables users to produce real-world evidence rapidly and efficiently.
According to the company, this innovation cuts down the time it takes to create observational studies, providing answers in minutes using a chat-based interface.
Unlike other widely recognized large language models (LLMs) like ChatGPT and Google Gemini , ChatRWD is specifically built to address clinical questions more accurately, thanks to its access to Atropos Health’s extensive evidence network, which contains over 300 million anonymous patient records. The AI’s accuracy is further validated by its “real world fitness score” (RWFS), an indicator of the quality of data used to generate answers. The average RWFS score of 79.8 from the beta program highlights the high reliability of the platform.
Proven Results in Beta Testing During the beta phase, over 2,000 questions were answered by testers from a wide range of health systems and life science organizations. Testers reported significant time savings compared to traditional methods of obtaining clinical information, such as literature reviews and second opinion consults. The average time for generating a study was just 5.23 minutes.
“Real-world data research isn’t new, but producing publication-grade evidence from it typically takes weeks or months,” said Brigham Hyde, Ph.D., CEO and co-founder of Atropos Health. “With LLMs and automation, we’ve sped up that process significantly. ChatRWD not only produces evidence faster but does so with unmatched quality and trust.”
A comparison conducted during the beta program found that general-purpose LLMs like ChatGPT-4 and Claude 3 Opus provided relevant, evidence-based answers less than 10% of the time. In contrast, ChatRWD successfully completed 94% of the answers, with independent physician reviewers determining that ChatRWD produced the best answers in 87% of the cases.
Hyde emphasized that trust, quality, and accuracy are key differentiators of ChatRWD. “We’ve proven that ChatRWD is ready for prime time because it consistently delivers transparent, data-backed answers that clinicians can trust.”
A New Era for AI in Healthcare Physicians who participated in the beta phase praised ChatRWD for providing clear, concise answers supported by solid data and transparent statistics. “Everything needs to be backed up by transparency and accuracy,” Hyde noted, underscoring the platform’s commitment to reliability.
Clinicians and researchers are now invited to register for access to ChatRWD, which is positioned to play a pivotal role in the rapidly evolving fields of real-world evidence research and artificial intelligence.
Neil Sanghavi, president of Atropos Health, highlighted the importance of high-quality clinical evidence amid the rapid advancement of AI in healthcare. “ChatRWD’s performance exceeded our expectations, both technically and in terms of user satisfaction, which brings us to this exciting launch,” he said.
As AI continues to transform the healthcare landscape, Atropos Health remains at the forefront, delivering solutions that combine the power of artificial intelligence with the rigor of real-world evidence research.
